menu search

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune surveillance Application of the enLIGHTEN™ Advanced Analytics suite to datasets from immune checkpoint inhibitor (ICI)-treated patients enabled in silico prediction and subsequent preclinical validation of multi-gene payload combinations to overcome lack of response to ICI […] The post Candel Therapeutics Presents Preclinical Data from... Read More
Posted: Nov 4 2023, 12:00
Author Name: forextv
Views: 091684

Search within

Pages Search Results: